Evaluation of glycosylated hemoglobin levels in hypothyroidism after thyroxine replacement
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 6, Pages 2504-2508
AbstractIntroduction: After diabetes mellitus, thyroid diseases are the second most frequent endocrine system disorders in the general population. The most prevalent type of glycated haemoglobin is haemoglobin A1C (HbA1c). HbA1c levels are influenced by factors that affect erythrocyte turnover or survival as well as the current glycemia, leading to values of HbA1c that are artificially high or low. Both the American Diabetes Association (ADA) and the World Health Organization have approved the use of HbA1c for the detection and treatment of diabetes.
Material and Materials: The prospective study includes 100 subjects diagnosed with hypothyroidism, Blood sample (random) was taken from each individual and parameters like Complete blood count, reticulocyte count, fasting blood glucose, post prandial blood glucose, HBA1C, TSH, and T4 were determined by spectrophotometric and by using Biochemistry Fully Automated Analyser.
Results: The mean age of the participants observed in the present study was found to be 43.23; The mean FBS values were raised significantly in the post treatment period. The mean value of HbA1C decreased significantly after treatment when compared to the pre-treatment levels.
Conclusion: To conclude, the findings of the study, HbA1c levels in patients with hypothyroidism are falsely elevated out of proportion to their level of glycemia, resulting in a false diagnosis of dysglycemia. However, after thyroxine replacement and the achievement of a euthyroidal state, HbA1c levels are lowered without any change in blood sugar levels.
- Article View: 5
- PDF Download: 12